Using breath carbon monoxide to predict liver recovery after partial hepatectomy
Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy
NA · Englewood Hospital and Medical Center · NCT06681818
This will test whether measuring carbon monoxide in breath can help predict how well adults recover liver function after part of their liver is removed.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 125 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Englewood Hospital and Medical Center (other) |
| Locations | 1 site (Englewood, New Jersey) |
| Trial ID | NCT06681818 on ClinicalTrials.gov |
What this trial studies
The study will measure endogenous carbon monoxide production with a commercial breath CO monitor (smokerlyzer) in adults undergoing partial liver resection. Investigators will relate breath CO levels to the extent of hepatic resection and to postoperative measures of liver regeneration and function. Measurements will be taken before and after surgery to track changes over time and correlated with clinical outcomes. The approach seeks a noninvasive biomarker that could indicate patients at higher risk for liver-related morbidity after resection.
Who should consider this trial
Good fit: Adults planning partial liver resection for primary liver tumors or metastatic disease who can understand and sign informed consent are ideal candidates.
Not a fit: Patients under 18, those unable to consent or perform breath testing, or those with factors that prevent accurate CO measurement are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, this could provide a simple, noninvasive breath test to help identify patients likely to regenerate liver tissue well or at risk for postoperative liver complications.
How similar studies have performed: Some prior work has measured heme oxygenase activity and breath CO in liver disease, but using breath CO specifically to predict post-hepatectomy regeneration is relatively novel and not yet proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient plans to have partial liver resection for primary liver pathology or metastatic disease * Patient is able to comprehend and willing to sign the written consent form Exclusion Criteria: * Patients \< 18 years * Patients identified as members of a vulnerable population, except women of child bearing potential with negative pregnancy test
Where this trial is running
Englewood, New Jersey
- Englewood Hospital — Englewood, New Jersey, United States (RECRUITING)
Study contacts
- Principal investigator: Cherif Boutros, MD — Englewood Hospital
- Study coordinator: Jamie Ketas
- Email: jamie.ketas@ehmchealth.org
- Phone: 2018943418
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Liver Cancer Adult, Liver Regeneration, hepatectomy